Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Aristotle Atlantic Partners LLC

Aristotle Atlantic Partners LLC trimmed its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 4.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 851,995 shares of the company's stock after selling 41,513 shares during the quarter. Aristotle Atlantic Partners LLC owned approximately 0.69% of Guardant Health worth $26,028,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of GH. NewEdge Advisors LLC increased its position in Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after purchasing an additional 230 shares during the period. Summit Investment Advisors Inc. lifted its holdings in Guardant Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock valued at $377,000 after acquiring an additional 391 shares during the period. Arizona State Retirement System grew its stake in shares of Guardant Health by 1.1% during the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock worth $1,089,000 after purchasing an additional 403 shares during the period. Jones Financial Companies Lllp grew its stake in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after purchasing an additional 817 shares during the period. Finally, Fiduciary Alliance LLC increased its holdings in shares of Guardant Health by 7.6% in the 4th quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock valued at $363,000 after purchasing an additional 836 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Guardant Health Stock Performance

Shares of NASDAQ:GH traded down $2.07 during mid-day trading on Tuesday, hitting $41.98. 4,053,148 shares of the company traded hands, compared to its average volume of 2,210,967. The firm's 50 day simple moving average is $43.76 and its 200 day simple moving average is $38.54. The firm has a market cap of $5.20 billion, a P/E ratio of -11.79 and a beta of 1.49. Guardant Health, Inc. has a 52-week low of $18.01 and a 52-week high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. The business had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business's revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.46) earnings per share. Equities research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GH shares. The Goldman Sachs Group upped their price target on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a report on Friday, February 21st. TD Securities upped their target price on Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Stephens reiterated an "overweight" rating and issued a $55.00 price objective on shares of Guardant Health in a research report on Wednesday, March 26th. Barclays lifted their target price on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, May 1st. Finally, Canaccord Genuity Group lifted their price objective on Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Twenty-one investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Guardant Health presently has a consensus rating of "Buy" and an average price target of $52.32.

Insider Buying and Selling

In related news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the sale, the chief executive officer now owns 2,202,672 shares in the company, valued at $107,952,954.72. This represents a 4.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 107,132 shares of company stock worth $5,249,355. Insiders own 5.50% of the company's stock.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.